Glen P Davis1, Michael T Compton, Shuai Wang, Frances R Levin, Carlos Blanco. 1. Department of Psychiatry, Division on Substance Abuse, Columbia University Medical Center/NYSPI, 1051 Riverside Drive, Unit 66, New York, NY 10032, United States. Electronic address: gpd2114@columbia.edu.
Abstract
BACKGROUND: Studies to date showing an association between cannabis use and schizophrenia-spectrum disorders are of relatively small sample sizes with limitations in generalizability. The present study addresses this gap by examining the relationship between cannabis use and psychotic-like symptoms in a large representative community sample. METHOD: Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, Wave 2), a large, nationally representative sample of 34,653 adults from the United States population. We evaluated the association between lifetime cannabis use, psychosis, and schizotypal personality features. RESULTS: The prevalence of psychosis and schizotypal personality disorder increased significantly with greater cannabis use in a dose-dependent manner. The associations between cannabis use and psychosis were 1.27 (95% CI 1.03-1.57) for lifetime cannabis use, 1.79 (95% CI 1.35-2.38) for lifetime cannabis abuse, and 3.69 (95% CI 2.49-5.47) for lifetime cannabis dependence. There was a similar dose-response relationship between the extent of cannabis use and schizotypal personality disorder (OR=2.02 for lifetime cannabis use, 95% CI 1.69-2.42; OR=2.83 for lifetime cannabis abuse, 95% CI 2.33-2.43; OR=7.32 for lifetime cannabis dependence, 95% CI 5.51-9.72). Likelihood of individual schizotypal features increased significantly with increased extent of cannabis use in a dose-dependent manner. CONCLUSION: This is the first population-based study to examine the association between lifetime cannabis use, psychosis, and schizotypal personality traits. These results add to evidence that cannabis use may be a risk factor for psychosis liability.
BACKGROUND: Studies to date showing an association between cannabis use and schizophrenia-spectrum disorders are of relatively small sample sizes with limitations in generalizability. The present study addresses this gap by examining the relationship between cannabis use and psychotic-like symptoms in a large representative community sample. METHOD: Data were derived from the 2004-2005 National Epidemiologic Survey on Alcohol and Related Conditions (NESARC, Wave 2), a large, nationally representative sample of 34,653 adults from the United States population. We evaluated the association between lifetime cannabis use, psychosis, and schizotypal personality features. RESULTS: The prevalence of psychosis and schizotypal personality disorder increased significantly with greater cannabis use in a dose-dependent manner. The associations between cannabis use and psychosis were 1.27 (95% CI 1.03-1.57) for lifetime cannabis use, 1.79 (95% CI 1.35-2.38) for lifetime cannabis abuse, and 3.69 (95% CI 2.49-5.47) for lifetime cannabis dependence. There was a similar dose-response relationship between the extent of cannabis use and schizotypal personality disorder (OR=2.02 for lifetime cannabis use, 95% CI 1.69-2.42; OR=2.83 for lifetime cannabis abuse, 95% CI 2.33-2.43; OR=7.32 for lifetime cannabis dependence, 95% CI 5.51-9.72). Likelihood of individual schizotypal features increased significantly with increased extent of cannabis use in a dose-dependent manner. CONCLUSION: This is the first population-based study to examine the association between lifetime cannabis use, psychosis, and schizotypal personality traits. These results add to evidence that cannabis use may be a risk factor for psychosis liability.
Authors: Ronald C Kessler; Howard Birnbaum; Olga Demler; Ian R H Falloon; Elizabeth Gagnon; Margaret Guyer; Mary J Howes; Kenneth S Kendler; Lizheng Shi; Ellen Walters; Eric Q Wu Journal: Biol Psychiatry Date: 2005-07-14 Impact factor: 13.382
Authors: Deepak Cyril D'Souza; Walid Michel Abi-Saab; Steven Madonick; Kimberlee Forselius-Bielen; Anne Doersch; Gabriel Braley; Ralitza Gueorguieva; Thomas B Cooper; John Harrison Krystal Journal: Biol Psychiatry Date: 2005-03-15 Impact factor: 13.382
Authors: Bridget F Grant; Deborah S Hasin; Carlos Blanco; Frederick S Stinson; S Patricia Chou; Rise B Goldstein; Deborah A Dawson; Sharon Smith; Tulshi D Saha; Boji Huang Journal: J Clin Psychiatry Date: 2005-11 Impact factor: 4.384
Authors: Chandlee C Dickey; Robert W McCarley; Margaret A Niznikiewicz; Martina M Voglmaier; Larry J Seidman; Sunnie Kim; Martha E Shenton Journal: Schizophr Res Date: 2005-10-15 Impact factor: 4.939
Authors: Cécile Henquet; Lydia Krabbendam; Janneke Spauwen; Charles Kaplan; Roselind Lieb; Hans-Ulrich Wittchen; Jim van Os Journal: BMJ Date: 2004-12-01
Authors: Pia M Mauro; Hannah Carliner; Qiana L Brown; Deborah S Hasin; Dvora Shmulewitz; Reanne Rahim-Juwel; Aaron L Sarvet; Melanie M Wall; Silvia S Martins Journal: J Stud Alcohol Drugs Date: 2018-05 Impact factor: 2.582